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tion alone accounted for this and whether the reduction would have been greater had the diuretics not caused a ''backlash'' of cardiotoxicty. Certainly, the introduction of orally available thiazide diuretics in 1957 -8 revn November 1985, we reviewed the then current status of experimental and clinical evidence and opinion on diuretic-associated hypokalemia with particular attention to its potential for inducing ventricular ectopy. 1 Nearly a decade later we had the olutionized the treatment of hypertension. Earlier oral drug regimens caused such significant deterioration of opportunity to revisit this topic in preparation for the Third Dahl Symposium; nearly 12 years later, we have the quality of life of patients with otherwise asymptomatic hypertension that convincing patients to be miserareviewed the current literature in preparation of this paper. What has changed? Not much in the way of ble in order to live longer was a difficult sales pitch.
To paraphrase the late Herbert Langford, how can one solid data, but there does appear to be some alteration of the paradigm. This paper is a review of work by expect a patient to take medications that make them unable to cerebrate, defecate, or fornicate in the hope ourselves and others, but the reader must keep firmly in mind that, in the final analysis, it is an expression of living longer? Of course, one could add the visual of my personal opinion.
and urinary sphincter changes plus orthostatic hypotension and depression to that short list. Oral diuretics WHAT ARE THE ISSUES? changed all of that by providing single-drug control for I see the issues as follows. First, there is the concern patients with milder hypertension and by permitting over why cardiovascular mortality has not been re-lower doses of other drugs when combined with them. duced by antihypertensive therapy over time to the In my opinion, none of the hypertension studies dedegree predicted when the reduction of cerebrovascu-signed, completed, and published to date can be interlar mortality has met expectations. Second, there was preted to show true cardiotoxicity of diuretics. First, considerable concern over the promotion of potas-the patient population was middle-aged and patients sium supplements and potassium-sparing diuretics with cardiac risk factors were not excluded. Indeed, because they were expensive and thought to be unnec-patients with known coronary heart disease manifested essary. Third, there was considerable controversy by an old myocardial infarction or angina pectoris were about whether or not diuretics alone or associated specifically included. Second, very large doses of diwith hypokalemia could cause lethal or potentially uretics were generally used. A recent case-controlled lethal ventricular ectopy. Finally, the fact that there is study suggests that the use of 25 mg or less of hydroa current trend toward using non-diuretic antihyper-chlorothiazide may actually be cardioprotective. 2 Third, tensive drugs and using only low-dose diuretics, many trials were not really designed to test a specific could render most of the above discussion moot.
hypothesis regarding cardiac mortality. Fourth, some of the diuretics used were combined with potassiumCardiovascular Mortality That the era of more insparing agents and some were not. The major clinical tense antihypertensive therapy has been accompanied trial, Antihypertensive and Lipid Lowering Treatment by a reduction in cardiovascular mortality is indisputto Prevent Heart Attack Trial ( ALLHAT ) , is designed able. The questions are whether blood pressure reducto detect differences in cardiovascular mortality between different classes of drugs, including diuretics, but it will not be completed until after the turn of the if the data had so indicated, the modern shift to the tassium was reduced with both diuretics, but magnesium was not. Four of the patients had increased VEA, use of lower doses may have rendered those studies irrelevant.
but this had no correlation with the serum potassium or magnesium levels. Potassium Supplements As the use of thiazide Emara and Saadet 17 reported three cases of atrial diuretics for both edematous states and hypertension fibrillation related to thiazide therapy and hypokabecame widespread, the issue of hypokalemia became lemia. Correction of the hypokalemia returned the important. A large commercial market for various po-rhythm to normal sinus. No underlying cardiac distassium supplements and potassium-sparing drugs ease was found. evolved and promotion of these drugs was feverish.
Dyckner and Wester, 18 who had made earlier conDespite some clever methods for disguising the tributions to this area in regard to magnesium, unpleasant taste of potassium salts, none were prob-pointed out that muscle magnesium levels were frelem-free. Those not based on potassium chloride were quently low in patients with congestive heart failure not very effective and those that bypassed gustatory who were treated with diuretics. They argued for the exposure often created gastroenteric problems such as use of potassium-sparing diuretics because they spare strictures or were not adsorbed at all. 3 Kassirer 4,5 in magnesium as well. Of course, serum magnesium particular brought the case against what he considered does not reflect intracellular magnesium accurately. to be a national obsession with potassium, but others Ragnarsson et al 19 were unable to show a correlation kept arguing that hypokalemia was frequent and poten-of serum magnesium in diuretic-treated older patially lethal.
6 Again, the paradigm has shifted to the tients, but they did find a higher rate of ventricular use of low-dose diuretics so that the issue is much less ectopy in the diuretic group than a group treated with volatile; in fact, it is nearly invisible. 
VENTRICULAR ECTOPY
studied 37 elderly patients whose mean age was 81 The late John Hollifield, 8 Brian Holland 9 and others years. Patients were given 50 mg hydrochlorothiazide generated studies that suggested that diuretics were alone or in combination with amiloride 5 mg. There associated with increased ventricular ectopic activity. was a placebo control group. Hydrochlorothiazide Messerli 10 and many others have demonstrated the alone reduced serum potassium significantly from 4.1 relationship of left ventricular hypertrophy to in-to 3.5 mmol / L compared to the combination and creased risk for both ventricular ectopic activity placebo group. The placebo group had a higher inci-( VEA ) and cardiac death. It was argued that many dence of serious ventricular arrhythmias ( 15 / 37; patients with hypertension had organic heart disease, 41% ) than those receiving thiazide alone ( 13 / 37; often silent, and that diuretic use would place them 35% ) or the combination ( 9 / 37; 24% ) . The conclusion at an increased risk for death. On the other hand, was that this dose of hydrochlorothiazide did not afEdward D. Freis, who really brought thiazide diuret-fect the frequency or severity of VEA in that elderly ics to clinical practice, Papademetriou, 11 Madias, 12 population. Caralis 13,14 and many others published studies that Poole-Wilson 21 took the position that most physicast doubt on any specificity of diuretics for increasing cians were already aware ( 1987 ) of the basic issues VEA. Indeed, the basic message was that, unless there so that, even if they were not fully understood, the was underlying organic heart disease, even rather physicians knew what to do about it and that ''it was marked hypokalemia would not trigger a significant no longer a major therapeutic issue.'' I suspect that increase in VEA.
this is where we are today! Animal experiments generally suggest that hypoka-
SELECTED INFORMATION SINCE 1985
lemia induced by diuretics is harmful. For example, Alexander 22 found that Wistar rats injected with variHollifield 15 was interested in the effects of diuretics on both potassium and magnesium. He studied 35 ous diuretics had reduced intracerebral magnesium and were more susceptible to arrhythmias induced by patients to whom he gave 12.5 to 50 mg of hydrochlorothiazide, increasing the dose every 4 weeks until digoxin. He could reverse this effect by giving intracerebral magnesium. Garan et al 23 used an acute myothe blood pressure was controlled. They were treated for 24 weeks. Each increase in diuretic dose further cardial infarction model in dogs. They depleted potassium with an extremely low potassium diet and hydecreased the blood pressure but also serum potassium and magnesium levels. Lumme and Jounela 16 drochlorothiazide. They found that both the total potassium deficit and serum potassium levels correused 24-h electrocardiogram ( ECG ) monitoring to study 24 hypertensive patients who were treated with lated significantly with spontaneous ventricular fibrillation after the infarct. Note that members of this either hydrochlorothiazide up to 50 mg / day or indacrinone, with or without amiloride. Mean serum po-group had earlier objected to the routine use of potas- 
of VEA associated with hydrochlorothiazide but not formed a randomized, double-blind controlled clininitrendipine in men with documented ischemic heart cal trial of 233 hypertensive men aged 35 to 70 years. disease.
They were randomly allocated to treatment for 2 Holland and colleagues 25 used a high dose ( 100 mg ) months in one of six groups: hydrochlorothiazide, hyof hydrochlorothiazide in a group of patients with drochlorothiazide plus potassium, hydrochlorothiapreviously documented diuretic-associated hypoka-zide plus potassium and magnesium, hydrochlorothilemia who did not have cardiac disease by ambulatory azide plus triamterene, chlorthalidone, or placebo. ECG monitoring or exercise stress tests. Amiloride The serum potassium levels in the hydrochlorothiawas used in a second group of patients to maintain zide alone group were 0.4 mmol / L lower than the normal potassium levels. The diuretic treated patients placebo group and this difference was not affected by developed hypokalemia with associated increased any of the three supplementation regimens. Neverthe-VEA; this was reversed by giving amiloride. One pa-less, the supplements did prevent the development of tient died an arrhythmic death while hypokalemic. serum potassium levels of 3.0 mmol / L or less which They again concluded that diuretics induce increased occurred in 12 / 90 ( 13% ) of the men who were treated VEA by virtue of the electrolyte abnormalities that with diuretic alone. This latter group also had a 2-they effect. Papademetriou and his colleagues 26 held fold increase in ventricular arrhythmias. The majority their prior position as well. In a study of 44 uncompli-of patients had no difference in ventricular arrhythcated hypertensive patients who were given 100 mg mias. The authors concluded that in most patients hydrochlorothiazide, they found no evidence that the ''treatment with 50 mg / day of hydrochlorothiazide diuretic or diuretic-associated hypokalemia resulted does not cause marked hypokalemia or ventricular in increased ventricular ectopy. This was true even arrhythmias.'' They do go on to caution that potasfor the patients with left ventricular hypertrophy who sium levels should be monitored and potassium-sparhad increased VEA at baseline. Peters et al 27 pub-ing strategies used when indicated. lished results similar to that of Papademetriou. They Two studies 33,34 compared an angiotensin-conrandomly allocated 19 men to treatment with hydro-verting enzyme inhibitor to hydrochlorothiazide in chlorothiazide 25 mg, 50 mg, or 25 mg plus 50 mg regard to cardiac arrhythmias and other factors. Altriamterene for 6 months. Serum potassium levels fell though they focused on the beneficial effects of the to õ3.5 mmol / L in about half of the patients, regard-ACE inhibitors, hydrochlorothiazide did not increase less of treatment group and there was no relationship VEA in either study. Papademetriou et al 35 did a simibetween serum potassium level and VEA by 24-h am-lar comparison of hydrochlorothiazide with an ACE bulatory monitoring. They concluded that low-dose inhibitor, calcium channel blocker and b-blocker in diuretic therapy for hypertension is not arrhythmo-31 patients with documented LVH. Although diltiagenic. Messerli and coworkers 28 studied patients with zem and metoprolol significantly decreased ventriculeft ventricular hypertrophy. Patients were given eilar ectopy, both enalapril and hydrochlorothiazide ther a calcium channel blocker, which reduced VEA, were neutral. or hydrochlorothiazide, which did not change the rate
In his most recent and very careful review of this of VEA even in this group with LVH. Papademetriou, topic, 36 Dr. Freis again supported the continuing use Notargiacomo, and Freis 29 extended their studies to of diuretics for the treatment of hypertension. He parexercise stress testing of patients treated with either ticularly endorsed the use of small doses as being hydrochlorothiazide or placebo. They did not find any prudent. Even this position elicited a pointed rebuttal difference between the two groups in frequency or to which his measured answer is a typical masterpiece complexity of arrhythmias. from a master. 37 Lumme and Journela 30 extended their studies with 11 hypertensives with known increased VEA at base-WHO BENEFITS? line. They gave 50 mg hydrochlorothiazide daily plus either potassium or a combination of potassium and One of the key questions in sociology research is: who magnesium. The potassium supplementation did help benefits? The question often generates some interestto control the VEA, but the addition of magnesium ing perspectives that might otherwise be missed. It is offered no additional benefit.
clear that either a successful stepped-care algorithm Ed Freis 31 reviewed this topic carefully in 1990 and or a Joint National Committee recommendation that concluded once again that further evidence from amsuggests use of a diuretic as a first step will eliminate bulatory ECG monitoring ''does not support the hyabout 50% of the potential market for more recent and pothesis that thiazide diuretics, either in the presence generally more profitable antihypertensive drugs. By or absence of hypokalemia, increase the frequency or severity of ventricular arrhythmias.'' creating fear of diuretics, those that market nondi- 
